Bristol-Myers Squibb Co (BMY) Shares Sold by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. decreased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 2.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,065 shares of the biopharmaceutical company’s stock after selling 822 shares during the quarter. Bristol-Myers Squibb makes up about 1.3% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 22nd biggest position. Sterling Investment Advisors Ltd.’s holdings in Bristol-Myers Squibb were worth $1,916,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in BMY. Blue Chip Partners Inc. increased its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 15 shares during the last quarter. Chilton Investment Co. LLC increased its stake in shares of Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 26 shares during the last quarter. Keel Point LLC increased its stake in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares during the last quarter. Finally, Hudock Capital Group LLC increased its stake in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 49 shares during the last quarter. Institutional investors own 69.67% of the company’s stock.

Bristol-Myers Squibb Co (NYSE:BMY) opened at $62.47 on Friday. Bristol-Myers Squibb Co has a 12 month low of $46.01 and a 12 month high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market cap of $102,240.00, a price-to-earnings ratio of 24.59, a P/E/G ratio of 2.22 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.77 earnings per share. equities analysts anticipate that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.56%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.

BMY has been the topic of several analyst reports. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Jefferies Group restated a “buy” rating and set a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price target on the stock in a research note on Wednesday, September 27th. UBS Group restated a “buy” rating and set a $72.00 price target (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Finally, SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $65.05.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the sale, the executive vice president now owns 9,251 shares in the company, valued at $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Co (BMY) Shares Sold by Sterling Investment Advisors Ltd.” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2018/01/12/bristol-myers-squibb-co-bmy-shares-sold-by-sterling-investment-advisors-ltd.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit